ESMO 2022 | Advantages of metronomic chemotherapy in ER+/HER2- metastatic breast cancer

Elisabetta Munzone, MD, Istituto Europeo di Oncologia, Milan, Italy, discusses the benefits of treating ER+/HER2- metastatic breast cancer with metronomic chemotherapy compared to the standard of care. This additional regimen enables oral treatment at home, only requiring one monthly hospital visit, which brings additional convenience for patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.